In 2021, the oral solid dosage pharmaceutical market was valued at US$ 524.6 billion, with a projected growth to reach US$ 1.03 trillion by 2032. The expected compound annual growth rate (CAGR) during the period from 2022 to 2032 is estimated at 6.4%, indicating substantial expansion.
The global market for oral solid dosage (OSD) pharmaceuticals has experienced notable growth recently, fueled by increasing healthcare demands, advancements in drug delivery technologies, and a growing elderly population. Tablets, capsules, and powders, collectively known as OSD formulations, have become pivotal in pharmaceutical treatments due to their convenience, stability, and easy administration.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7553
Market Opportunity:
The promising prospects within the oral solid dosage (OSD) pharmaceutical market are influenced by several key factors. Firstly, the rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, and respiratory ailments necessitates the development of efficient and patient-friendly drug delivery methods. OSD formulations address this need by providing precise dosing, improving patient compliance, and reducing healthcare costs. Additionally, the increasing demand for generic drugs, driven by the expiration of patents for blockbuster medications, creates a lucrative opportunity for OSD manufacturers to capitalize on.
Furthermore, the growing emphasis on personalized medicine and the integration of innovative technologies like 3D printing in tablet manufacturing present novel possibilities. Customized dosage forms tailored to individual patient needs have the potential to enhance treatment outcomes and improve patient adherence. Emerging markets, particularly in Asia-Pacific and Latin America, represent untapped potential. This is fueled by the rising awareness of healthcare, improving economic conditions, and expanding access to healthcare services in these regions.
Market Challenges:
While the OSD pharmaceutical market is on a growth trajectory, it faces several challenges that necessitate strategic navigation. Regulatory hurdles pose a significant impediment, with stringent guidelines governing product quality, manufacturing processes, and safety standards. The complex and evolving nature of regulations, especially in regions like Europe and the United States, demands continuous adaptation from industry players.
Additionally, the threat of counterfeit drugs remains a persistent challenge, jeopardizing patient safety and undermining trust in pharmaceutical products. Manufacturers must invest in robust supply chain management and anti-counterfeiting technologies to safeguard the integrity of their products.
Furthermore, the inherent variability in patient responses to oral medications poses a challenge in optimizing drug efficacy. Achieving a balance between personalized medicine and mass production efficiency is a delicate task that requires ongoing research and development efforts.
Key Players:
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences
- Merck & Co. Inc
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Boehringer Ingelheim GmbH
- Hoffman-La-Roche Ltd.
- Johnson & Johnson
Competitive Landscape:
Prominent manufacturers of oral solid dosage pharmaceutical products are currently engaged in strategic efforts to enhance their product portfolios through the attainment of regulatory approvals for novel offerings and the establishment of partnerships with industry leaders.
In March 2022, AstraZeneca successfully obtained authorization from the European Union government to market Evusheld, a long-acting antibody combination designed for the prevention of COVID-19 across a wide population.
Furthermore, in June 2022, Bristol Myers Squibb unveiled a definitive merger agreement to acquire Turning Point Therapeutics, a clinical-stage precision oncology company. This acquisition is poised to bolster Bristol Myers Squibb’s oncology medicines segment, leveraging the expertise and capabilities of Turning Point Therapeutics in the field of precision oncology.
Key Segments in Oral Solid Dosage Pharmaceutical Industry Research
- By Dosage Form :
- Tablets
- Conventional/Immediate Release
- Modified Release
- Chewable Tablets
- Effervescent Tablets
- Capsules
- Hard Gelatin Capsules
- Soft Gelatin Capsules
- Others
- Powders & Granules
- Lozenges & Pastilles
- Gummies
- Tablets
- By Drug Release Mechanism :
- Immediate Release
- Delayed Release
- Controlled Release
- By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- Hypermarkets / Supermarkets
- By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=7553
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team : [email protected]
Follow Us: LinkedIn | Twitter | YouTube